Oruka Therapeutics (ORKA) CMO exercises options and sells 7,641 shares
Rhea-AI Filing Summary
Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised equity awards and sold shares in a pre-planned, tax-related transaction. She exercised employee stock options and an employee warrant covering a total of 7,000 shares of common stock at exercise prices of $6.84 and $7.80 per share.
On the same date, she sold 7,641 shares of common stock in multiple open-market transactions at weighted average prices between approximately $39.65 and $42.28. The filing states these sales were made under a Rule 10b5-1 trading plan and Oruka’s automatic, non-discretionary sell-to-cover procedure for tax withholding. Following the transactions, she directly holds 33,377 common shares.
Positive
- None.
Negative
- None.
Insights
Routine option exercises with tax-related, pre-planned share sales; modest net reduction in holdings.
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, exercised employee options and a warrant for 7,000 common shares at exercise prices of $6.84 and $7.80. This converts derivative compensation into actual stock, a standard part of equity-based pay.
She then sold 7,641 common shares in several open-market trades at weighted average prices between $39.65 and $42.28. Footnotes explain these sales were executed under a Rule 10b5-1 trading plan and the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding on restricted stock unit vesting, indicating mechanistic rather than discretionary timing.
After these transactions, Goncalves directly holds 33,377 common shares. Because the sales are tied to compensation and tax obligations and follow a pre-established plan, they typically carry limited informational value about her view of Oruka Therapeutics’ prospects. Overall, this appears to be routine equity compensation management rather than a thesis-changing insider move.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 3,500 | $0.00 | -- |
| Exercise | Employee Warrant (right to buy) | 3,500 | $0.00 | -- |
| Exercise | Common Stock | 3,500 | $6.84 | $24K |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 2,921 | $40.1091 | $117K |
| Sale | Common Stock | 2,902 | $41.2022 | $120K |
| Sale | Common Stock | 1,177 | $41.9361 | $49K |
| Sale | Common Stock | 641 | $41.30 | $26K |
Footnotes (1)
- These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.70, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $42.28, inclusive. These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
